Neuropathic pain: a practical guide for the clinician

被引:291
作者
Gilron, Ian
Watson, C. Peter N.
Cahill, Catherine M.
Moulin, Dwight E.
机构
[1] Kingston Gen Hosp, Dept Anesthesiol, Kingston, ON K7L 2V7, Canada
[2] Queens Univ, Dept Anesthesiol, Kingston, ON K7L 3N6, Canada
[3] Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada
[4] Univ Toronto, Dept Med, Toronto, ON, Canada
[5] London Reg Canc Program, London, ON, Canada
[6] Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada
[7] Univ Western Ontario, Dept Oncol, London, ON, Canada
关键词
D O I
10.1503/cmaj.060146
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Neuropathic pain, caused by various central and peripheral nerve disorders, is especially problematic because of its severity, chronicity and resistance to simple analgesics. The condition affects 2%-3% of the population, is costly to the health care system and is personally devastating to the people who experience it. The diagnosis of neuropathic pain is based primarily on history (e.g., underlying disorder and distinct pain qualities) and the findings on physical examination ( e. g., pattern of sensory disturbance); however, several tests may sometimes be helpful. Important pathophysiologic mechanisms include sodium- and calcium-channel upregulation, spinal hyperexcitability, descending facilitation and aberrant sympathetic-somatic nervous system interactions. Treatments are generally palliative and include conservative non-pharmacologic therapies, drugs and more invasive interventions (e.g., spinal cord stimulation). Individualizing treatment requires consideration of the functional impact of the neuropathic pain (e.g., depression, disability) as well as ongoing evaluation, patient education, reassurance and specialty referral. We propose a primary care algorithm for treatments with the most favourable risk-benefit profile, including topical lidocaine, gabapentin, pregabalin, tricyclic antidepressants, mixed serotonin-norepinephrine reuptake inhibitors, tramadol and opioids. The field of neuropathic pain research and treatment is in the early stages of development, with many unmet goals. In coming years, several advances are expected in the basic and clinical sciences of neuropathic pain, which will provide new and improved therapies for patients who continue to experience this disabling condition.
引用
收藏
页码:265 / 275
页数:11
相关论文
共 141 条
[1]   Dysaesthesia associated with sternotomy for heart surgery [J].
Alston, RP ;
Pechon, P .
BRITISH JOURNAL OF ANAESTHESIA, 2005, 95 (02) :153-158
[2]  
*AM PAIN SOC, 1997, US OP TREATM CHRON P
[4]  
[Anonymous], BONICAS MANAGEMENT P
[5]   The Quebec Task Force classification for spinal disorders and the severity, treatment, and outcomes of sciatica and lumbar spinal stenosis [J].
Atlas, SJ ;
Deyo, RA ;
Patrick, DL ;
Convery, K ;
Keller, RB ;
Singer, DE .
SPINE, 1996, 21 (24) :2885-2892
[6]   Mechanisms of pain in peripheral neuropathy [J].
Attal, N ;
Bouhassira, D .
ACTA NEUROLOGICA SCANDINAVICA, 1999, 100 :12-24
[7]   Pain assessment and evaluation of patients who have neuropathic pain [J].
Backonja, MM ;
Galer, BS .
NEUROLOGIC CLINICS, 1998, 16 (04) :775-+
[8]   Neuropathic pain questionnaire - Short form [J].
Backonja, MM ;
Krause, SJ .
CLINICAL JOURNAL OF PAIN, 2003, 19 (05) :315-316
[9]   Opioid therapy for chronic pain [J].
Ballantyne, JC ;
Mao, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (20) :1943-1953
[10]  
Baron R, 1999, MUSCLE NERVE, V22, P678, DOI 10.1002/(SICI)1097-4598(199906)22:6<678::AID-MUS4>3.0.CO